Innovative Endpoints in Alzheimer’s Disease Clinical Trials
Together with our partner Brain Research Center, we presented the webinar:
Innovative Endpoints in Alzheimer’s Disease Clinical trials.
During this webinar, two experts in the field, Dr. Niels Prins and Dr. Jort Vijverberg discussed the latest clinical and biomarker endpoints.
During this webinar our experts expanded on how we advance clinical drug development for Alzheimer’s disease by touching upon:
> Biomarker-based participant selection;
> inclusion criteria for upcoming AD trials
> Fluid biomarkers as endpoints in your AD trial;
> EEG; a ‘novel’ AD biomarker.
Related webinars
Webinar – Improving ALS Trial Delivery Through Insights from Patient and Industry Experience
On January 19, at 16.30 CET, we will present the webinar: Improving ALS Trial Delivery Through Insights from Patient and Industry ExperienceWhat You’ll LearnPatient- and Industry-Informed Insights Top patient-experience pitfalls obs...
Webinar – Boosting patient enrolment and retention in clinical trials: Expert Insights & Tips
On June 30, at 16.00 CEST, we will present the webinar: Boosting patient enrolment and retention in clinical trials: Expert Insights & TipsJoin us for an interactive discussion with experts who will draw upon recent cardiology and neurolog...
Webinar: The Role of EEG in Dementia Trials
How early can you detect whether a treatment is working in dementia trials, and what if you didn’t have to wait for traditional endpoints? Electroencephalography (EEG) is gaining momentum as a powerful tool to capture real-time changes in brain...
